| (P1428) |
Evaluation of clinical risk factors to predict high on-treatment platelet aggregability and outcome in patients with stable coronary artery disease (PREDICT-STABLE) |
|
M. Droppa, D. Tschernow, K. A. L. Müller, E. Tavlaki, A. Karathanos, F. Stimpfle, M. Gawaz, T. Geisler (Tübingen) |
| (P1429) |
Impact of dabigatran and phenprocoumon on ADP induced platelet aggregation in patients with atrial fibrillation (The Dabi-ADP-1 trial) |
|
N. Sarafoff, A. Martischnig, J. Pollak, D. Sibbing, S. Massberg, A. Kastrati, J. Mehilli (München) |
| (P1430) |
Platelet Reactivity In Patients With Acute Coronary Syndrome Treated With Prasugrel Or Ticagrelor In Comparison To Clopidogrel: A Pharmacodynamic Analysis |
|
F. Schmidtler, G. Selhorst, A. Leber, E. Hitzke, M. Schmidt, J. Rieber, E. Hoffmann, D. H. Antoni (München) |
| (P1431) |
Variability of on-treatment platelet reactivity under prasugrel and ticagrelor and association with pre-treatment platelet reactivity in a large real-world cohort of ACS patients undergoing PCI |
|
E. Tavlaki, J. Metzger, A. Valera, K. A. L. Müller, A. Karathanos, F. Stimpfle, M. Gawaz, T. Geisler (Tübingen) |
| (P1432) |
Identifikation von Prasugrel Low-Respondern und Assoziation mit Cytochrom P450-Polymorphismen -2C9 und -2B6 |
|
C. C. Franken, K. Overbeck, A. Kaiser, J.-C. Krüger, H. Neubauer, A. Mügge (Bochum) |
| (P1433) |
High rate of Ticagrelor and Prasugrel- Non-Responder in patients in therapeutic hypothermia after cardiac arrest |
|
K. Ibrahim, M. Christoph, S. Schmeinck, K. Schmieder, S. Kolschmann, K. Steiding, C. Pflücke, R. H. Strasser, C. Wunderlich (Dresden) |
| (P1434) |
Dabigatran and rivaroxaban do not influence TRAP, ADP and AA induced platelet aggregation in cardiac patients |
|
C. Olivier, P. Weik, P. Diehl, Q. Zhou, C. Bode, M. Moser (Freiburg im Breisgau) |
| (P1435) |
Extracellular Cyclophilin A activates platelets in vitro and in vivo |
|
P. Seizer, J. Schwille, A. Karathanos, H. Sturhan, S. v. Ungern Sternberg, O. Borst, T. Geisler, A. May (Tübingen) |
| (P1436) |
Obesity and a history of low response to clopidogrel treatment are predictors for a reduced antiplatelet action of prasugrel treatment |
|
M. Orban, I. Bernlochner, S.-L. Braun, M. Hadamitzky, J. Mehilli, S. Massberg, A. Kastrati, D. Sibbing, K. Mayer (München) |
| (P1437) |
Delayed onset of antiplatelet effect of prasugrel and ticagrelor in patients with acute coronary syndromes |
|
D. Trenk, M. Ferenc, R. Schmitz, T. Nührenberg, S. Leggewie, C. Stratz, C. M. Valina, R.-P. Kienzle, W. Hochholzer, F.-J. Neumann (Bad Krozingen) |
| (P1438) |
Clinical Experience with Ticagrelor, a Novel Platelet Inhibitor, in Cardiac Surgical Patients: Boon and Bane of a new Potential Drug? |
|
H. Schotola, K. Meyer, A. Bräuer, J. Hinz, S. T. Sossalla, F. Schöndube, M. Quintel, M. Bauer, A.-F. Popov (Göttingen) |
| (P1439) |
The Effect of Bivalirudin and Heparin on Platelets Function During Coronary Intervention with Stenting (PCI) and on Tissue Factor (TF) Expression |
|
W. Pepke, A. Eisenreich, M. Jaster, Y. Ayral, P. Bobbert, H.-P. Schultheiss, U. Rauch-Kröhnert (Heidelberg, Berlin) |